OTCMKTS:PHGUF

Pharming Group Q4 2025 Earnings Results & Report

Pharming Group logo
$1.26 0.00 (0.00%)
As of 11/13/2026

Pharming Group beat analyst expectations on both earnings and revenue in its Q4 2025 results, released March 12, 2026. The company reported EPS of $0.0070 versus the $0.0015 consensus estimate, while revenue of $106.50 million topped the $89.72 million estimate by $16.78 million.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens

Pharming Group EPS Results

Actual EPS
$0.0070
Consensus EPS
$0.0015
Beat/Miss
Beat by +$0.0055
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 5 quarters

Pharming Group Revenue Results

Actual Revenue
$106.50 million
Expected Revenue
$89.72 million
Beat/Miss
Beat by +$16.78 million
YoY Revenue Growth
N/A

Conference Call Resources

Pharming Group Q4 2025 Earnings FAQ

Pharming Group (OTCMKTS:PHGUF) reported earnings of $0.0070 per share for Q4 2025, beating the consensus estimate of $0.0015. The report was announced on Thursday, March 12, 2026.

Pharming Group reported revenue of $106.50 million for Q4 2025, against a consensus estimate of $89.72 million.

Pharming Group Earnings Headlines

Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
See More Pharming Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pharming Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharming Group and other key companies, straight to your email.

About Pharming Group

Pharming Group (OTCMKTS:PHGUF) is a biotechnology company based in Leiden, the Netherlands, focused on developing and commercializing medicines for rare diseases. Its portfolio includes treatments for hereditary angioedema and activated phosphoinositide 3-kinase delta syndrome (APDS).

The company’s products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute hereditary angioedema attacks, and Joenja (leniolisib), an oral treatment for APDS. Pharming developed Ruconest using a production process involving genetically modified rabbits.

Founded in 1988, Pharming serves patients in markets including the United States and Europe, with additional access supported through commercial partners. Its work also includes research and development of medicines for other rare diseases.

View Pharming Group Profile